Analogous results were also obtained in additional nine cancer cell lines, including MDA‐MB‐231, Hs578T (TNBC), JIMT‐1, SK‐BR‐3 (HER2‐positive), MHCC97‐L (liver cancer), A549 (lung cancer), HeLa (cervical cancer), ES‐2 (ovarian cancer), and MiaPaCa‐2 (pancreatic cancer) (Figure 1I), highlighting that the effects of HSP90 N‐terminal inhibitors on MORC2 downregulation are not cell‐line specific. This evidence concerns the gene ERBB2 and lung carcinoma.